Literature DB >> 11486459

Case reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment for haematological malignancy.

L Mele, L Pagano, F Equitani, G Leone.   

Abstract

We report our recent experience with two cases of invasive pulmonary aspergillosis in patients who were both undergoing chemotherapy, one for acute myeloid leukaemia and the other for primary amyloidosis. Both patients had bad prognostic factors and were in very poor clinical condition, but both recovered from infection after a prolonged therapy with liposomal amphotericin B (AmBisome) without signs of toxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11486459     DOI: 10.1046/j.1439-0507.2001.00644.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  3 in total

1.  Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.

Authors:  Lizbeth Cahuayme-Zuniga; Russell E Lewis; Victor E Mulanovich; Dimitrios P Kontoyiannis
Journal:  Med Mycol       Date:  2011-11-22       Impact factor: 4.076

2.  Invasive coinfection with Aspergillus and Mucor in a patient with acute myeloid leukemia.

Authors:  Rui Bergantim; Elisabete Rios; Fernanda Trigo; Jose Eduardo Guimarães
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

3.  High weekly doses of liposomal amphotericin B as secondary prophylaxis after cerebral aspergillosis in a paediatric patient.

Authors:  Pierluigi Brazzola; Mario R Rossi
Journal:  Med Mycol Case Rep       Date:  2013-11-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.